-+ 0.00%
-+ 0.00%
-+ 0.00%

IDE849 (SHR-4849) DLL3 TOP1 ADC UPDATED PHASE 1 RESULTS AT ESMO 2026 DEMONSTRATES PROMISING ANTI-TUMOR ACTIVITY AND PRELIMINARY OVERALL SURVIVAL RESULTS IN RELAPSED SMALL CELL LUNG CANCER AND NEUROENDOCRINE CARCINOMAS

Reuters·10/23/2026 10:00:03

Please log in to view news